Merck Victrelis Glowing Recommendation From NICE At Odds With IQWiG
This article was originally published in The Pink Sheet Daily
Executive Summary
The contrasting views in Germany and England for the hepatitis C product underscore the difference between IQWiG’s purely scientific assessment and NICE’s focus on cost-effectiveness.
You may also be interested in...
Sovaldi On The Cusp: NICE Wants More Data On Subgroups
Gilead’s high-cost hepatitis C drug is surprisingly close to making it through U.K.’s cost-effectiveness watchdog.
AZ’s Brilinta Is First Drug To Clear AMNOG Assessment, While Merck’s Victrelis Limps Forward
Lack of consistent approach in IQWiG/G-BA AMNOG-based decisions leaves industry confused about new reimbursement route.
J&J vs. Merck: The Race Is On As Incivek Passes First EU Regulatory Hurdle
Merck's Victrelis is still likely to have a marketing advantage of one to two months over J&J's Incivek in the EU hepatitis C market, but pricing and reimbursement issues in the Member States will probably drive market share more than anything else.